Home/Pipeline/ALS Biomarker Program

ALS Biomarker Program

Amyotrophic Lateral Sclerosis

Pre-clinicalActive

Key Facts

Indication

Amyotrophic Lateral Sclerosis

Phase

Pre-clinical

Status

Active

Company

Linus Biotechnology

About Linus Biotechnology

LinusBio is a New York-based platform diagnostics company founded in 2019, focused on the novel field of temporal exposomics. Its core technology analyzes hair to reveal longitudinal molecular data, functioning as a biological recorder of environmental exposures and physiological changes. The company has achieved significant validation with FDA Breakthrough Device designation for its lead autism diagnostic biomarker and has launched its first commercial test, ClearStrand-ASD. LinusBio is leveraging its platform to build a pipeline targeting other complex CNS and systemic disorders.

View full company profile

Therapeutic Areas

Autism Spectrum Disorder Amyotrophic Lateral Sclerosis Attention Deficit Hyperactivity Disorder Schizophrenia Psychosis

Other Amyotrophic Lateral Sclerosis Drugs

Drug	Company	Phase	Status
Cell Therapy for ALS	INCELL	Unknown	Active
ALS Research	GliaPharm	Research	Active
ALS Disease Model Service	NeuroProof	Pre-clinical	Active
ALS Research (post-RADICAVA)	Tanabe Pharma America	Preclinical/Research	Active
ALS Program	Biorchestra	Preclinical	Active
Program(s) for ALS	AviadoBio	Pre-clinical	Active
TCD601 for ALS	ITB Med	Phase 2	Active
ILB® for ALS	TikoMed	Phase 2	Active
ALS Patient-Led Research Initiative	BGI	Research	Active
Foralumab (intranasal)	Tiziana Life Sciences	Phase 2	Planned (2H 2025)